

## Scandinavian Association of Urology Collaboration Group for Renal Cancer

### The Nordic Renal Cancer Group (NORENCA)

#### **Biannual report 2019-2022:**

*The NORENCA group is a collaboration group, and was established in Malmö in 2015. The focus has been on establishing a well-functioning scientific collaboration and working among the Scandinavian countries.*

**The activity has been very much influenced by the lockdown due to the COVID-19 in most of 2020 and partly 2021**

#### **Representation:**

**Sweden:** Pernilla Sundquist, Börje Ljungberg

**Finland:** Harry Nisen, Petrus Järvinen

**Denmark:** Lars Lund, Ness Azawi

**Norway:** Frode Nilsen, Christian Beisland

**Iceland:** Eirikur Gudmundsson

**Board: Chair:** Lars Lund (elected dec 2018 for 4 years)

**Vice-Chair:** Harry Nisen (elected dec 2018 for 4 years)

**3rd board member:** Vacant (elected for 4 years)

#### **Scientific meetings:**

The NORENCA hosted the 1st Nordic advanced renal cancer surgery course at Herlev Hospital, DK (the 25th and 26th, November, 2019). It was well attended with 64 participants from whole Scandinavian both with young surgeons in training as well as senior specialist. During the 2 days there was live operations and lectures. The evaluation was good and the group will plan a new meeting.

## **Meetings:**

There has been six on line meetings from 2019 to 2022. Please see summary form these meeting at the website of NUF.

The group planned an en-face meeting December 2021 in Steningevik but unfortunately, it was cancelled very late due to restrictions

June 2022 – Helsinki, Finland. Board meeting in conjunction with the 33 NUF congress.

Web site: <http://nuf.nu/collaboration%20groups/NoRenCa.html>

## **IKCS: Europe Scientific Program Committee**

2021. Lund L

2022. Lund L

## **Oral presentations**

2019 Herlev Copenhagen. Several lectures by the board during the renal session

2022. IEKCS, Antwerpen. Management of Incidental Renal Masses: A Summary. Lund L

2022. Baltic and EAU meeting. Cytoreductive nephrectomy in the modern area. Lund L

2022. NUF. Helsinki. Renal session with several lectures by the board.

## **Posters**

2022 IEKCS. Circulating tumor DNA in patients with renal cell carcinoma A systematic review of the literature. Lund L

## **Posters and oral presentation**

2022 NUF, Helsinki.

"Renal functional outcome after nephron sparing treatment of renal cell carcinoma: a systematic review". Lund L.

## **Invited Chairman:**

2021. IEKCS. On line meeting.

Surgical Session Panel Discussion. Chair: Lund L and Staehler M

Non-Clear Cell Panel Discussion. Chair: Lund L and Malouf G

New Directions/Management of Systemic Therapies. Chair: Lund L and Turajlic S

2022 IEKCS. Antwerpen.

Networking Session: Meet the Experts Breakfast. Lund L et al.

Networking Session: Poster Walks. Lund L

The Role of Radiation Therapy in the Management of Renal Cell Carcinoma. Chair  
Lund L

**Ongoing studies:**

- 1) Prospective Multicenter Study Comparing Surgery vs Active Surveillance In Patients With Bosniak 3 Renal Cyst. Principal investigator : Harry Nisen.
- 2) The NORDIC-SUN-Trial. Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a DaRenCa and NoRenCa Trial Evaluating the Impact of Surgery or No Surgery. Principal investigator: Niels Frstrup, Aarhus Denmark.

Lars Lund (Chair)